ClinicalTrials.gg
CompletedNCT06157918Updated Nov 8, 2024

Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants

A Phase 1 interventional study of SYHA1813 oral solution (2.0g:25mg) and SYHA1813 oral solution (20ml:200mg) in Healthy Participants, sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

This is a three-period crossover phase I study designed to evaluate the relative bioavailability, food effect, safety and tolerability of SYHA1813 oral solution in healthy participants.

Read the detailed description

Avoid duplicating information that will be entered elsewhere, such as Eligibility Criteria or Outcome Measures.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Shanghai Runshi Pharmaceutical Technology Co., Ltd is the lead sponsor of 9 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male aged 18 to 60 years old;
  2. Weight more than 50.0 kg and between 19 to 26.0 kg/m\^2;
  3. Normal or abnormal results without clinical significance on all tests including medical history, vital signs, physical examination, laboratory evaluation (routine blood, blood biochemistry, urine routine, coagulation function, serum virology, and other related tests), 12-lead , chest X-ray and other tests;
  4. Male participants and their partners must agree to use effective non-hormonal from the first administration of the test drug to 6 months after the last administration of the test drug, even if permanent contraception has already been used, and the male participant does not plan to donate sperm;
  5. Voluntarily sign the form, and cooperate in completing the trial according to the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Allergic constitution (allergic to 2 or more kinds of drugs, food, or pollen);
  2. Participants with a clear history of neurological disease or psychiatric disease, a history of severe cardiovascular, hepatic, renal, endocrine, respiratory, hematologic, digestive, immune, and other various systemic diseases, or a history of malignant neoplastic disease;
  3. Participants who are unable to swallow orally administered drugs, or abnormalities in gastrointestinal function that could affect drug absorption, distribution, metabolism, and excretion;
  4. Participants who have undergone major surgery within 6 months prior to screening or who are scheduled to undergo surgery during the trial;
  5. Participants with 1 or more abnormal vital signs at screening;
  6. Abnormal and clinically significant : >450ms;
  7. Participants who consumed more than 14 units of alcohol per week in the 4 weeks prior to screening or who had a positive breath test for alcohol at screening;
  8. Smoking ≥ 5 cigarettes per day on average within 6 months prior to screening;
  9. Participants with a history of drug or substance abuse, or a positive urine drug screen;
  10. Participants who have lost blood or donated more than 400 ml of blood within 4 weeks prior to screening or plan to donate blood during the study or within 1 month of the end of the study;
  11. Participants who have participated in other clinical trials within 3 months prior to screening;
  12. Habitual intake of excessive xanthine or caffeine-containing foods, beverages, or other foods that interfere with drug absorption, distribution, metabolism, excretion within 4 weeks prior to screening;
  13. Participants who have taken a special diet (dragon fruit, mango, grapefruit, lime, poppy seed, or food or drink prepared from them) within 7 days prior to screening, or participants who are unable to stop taking the above special diets during the trial;
  14. Participants who have used potent inhibitors or inducers of CYP enzymes (e.g., CYP2C9, 2C19, and 3A4) within 4 weeks prior to screening;
  15. Participants who have used prescription, over-the-counter, herbal, vitamin, or mineral medications within 2 weeks prior to screening, and participants who have taken medications prior to screening that have not completed 5 half-lives, whichever is longer among the various medications;
  16. Participants who cannot tolerate venipuncture or with a history of fainting needle or blood;
  17. Participants who are lactose intolerant;
  18. Any condition that the investigator considers inappropriate for participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Group 1-sequence ABC

    Participants will sequentially receive SYHA1813 oral solution (2.0g:25mg) fasted (Treatment A), followed by SYHA1813 oral solution (20ml:200mg) fasted (Treatment B), and SYHA1813 oral solution (2.0g:25mg) fed (Treatment C).

    Drug: SYHA1813 oral solution (2.0g:25mg) · Drug: SYHA1813 oral solution (20ml:200mg)

  • Experimental
    Group 2-sequence BCA

    Participants will sequentially receive SYHA1813 oral solution (20ml:200mg) fasted (Treatment B), followed by SYHA1813 oral solution (2.0g:25mg) fed(Treatment C), and SYHA1813 oral solution (2.0g:25mg) fasted (Treatment A).

    Drug: SYHA1813 oral solution (2.0g:25mg) · Drug: SYHA1813 oral solution (20ml:200mg)

  • Experimental
    Group 3-sequence CAB

    Participants will sequentially receive SYHA1813 oral solution (2.0g:25mg) fed (Treatment C), followed by SYHA1813 oral solution (2.0g:25mg) fasted (Treatment A), and SYHA1813 oral solution (20ml:200mg) fasted (Treatment B).

    Drug: SYHA1813 oral solution (2.0g:25mg) · Drug: SYHA1813 oral solution (20ml:200mg)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed plasma concentration

    Time frame: Up to 120 hours post-dose for eachperiod

  2. AUC0-∞

    Area under the plasma concentration time curve from time zero extrapolated to infinite time

    Time frame: Up to 120 hours post-dose for eachperiod

  3. AUC0-t

    Area under the plasma concentration time curve from time zero to the time of the last quantifiable concentration

    Time frame: Up to 120 hours post-dose for eachperiod

Secondary outcomes

  1. Tmax

    Time of maximum observed plasma concentration

    Time frame: Up to 120 hours post-dose for eachperiod

  2. T1/2

    Terminal elimination half-life

    Time frame: Up to 120 hours post-dose for eachperiod

  3. Title:Cl/F

    Apparent total body clearance

    Time frame: Up to 120 hours post-dose for eachperiod

  4. V/F

    Apparent volume of distribution

    Time frame: Up to 120 hours post-dose for eachperiod

  5. Number of participants with Adverse Events

    Time frame: Up to 34 days

07

Study locations

1 site
  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Jan 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Dec 6, 2023
StartActual
Dec 20, 2023
Primary completionActual
Jan 26, 2024
CompletionActual
Jan 26, 2024
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06157918
Lead sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Responsible party
Sponsor
First posted
Dec 6, 2023
Start date
Dec 20, 2023
Primary completion
Jan 26, 2024
Completion
Jan 26, 2024
Last update
Nov 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYHA1813

Start the discussion